---
title: Rivaroxaban Post Coronary Bypass Surgery
nct_id: NCT06019741
overall_status: COMPLETED
phase: PHASE4
sponsor: Shiraz University of Medical Sciences
study_type: INTERVENTIONAL
primary_condition: Post Coronary Bypass Surgery Patients
countries: Iran
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06019741.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06019741"
ct_last_update_post_date: 2023-09-06
last_seen_at: "2026-05-12T07:06:44.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Rivaroxaban Post Coronary Bypass Surgery

**Official Title:** Rivaroxaban and Aspirin Versus Aspirin Alone in Preventing Atherothrombotic Events in Patients Following Coronary Artery Bypass Graft Surgery

**NCT ID:** [NCT06019741](https://clinicaltrials.gov/study/NCT06019741)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 234
- **Lead Sponsor:** Shiraz University of Medical Sciences
- **Conditions:** Post Coronary Bypass Surgery Patients
- **Start Date:** 2021-02-01
- **Completion Date:** 2022-07-20
- **CT.gov Last Update:** 2023-09-06

## Brief Summary

Post coronary bypass patients were randomized to receiving aspirin alone or aspirin and low dose rivaroxaban

## Detailed Description

This study is a 1-year randomized, double-blind placebo-controlled trial to evaluate the effects of adding rivaroxaban to the treatment of patients after coronary bypass surgery. All patients referred for either off-pump or on-pump coronary bypass surgery to 3 academic hospitals in Shiraz, Iran were screened according to inclusion criteria. Clinicians at these sites were informed of this study and asked to refer patients after coronary bypass surgery.

A total of 414 patients were initially included in the study, but 171 of them were excluded based on the exclusion criteria (Figure 1). The remaining 243 patients were then randomly divided into two groups: group 1, receiving aspirin 80 mg daily plus placebo; group 2, receiving aspirin 80 mg daily plus rivaroxaban 2.5 mg twice daily.

Clinical outcomes were assessed at the end of first year post-operation. Subjects will undergo a complete history and physical examination and the study variables were assessed. Patients were followed every 2 weeks for any occurrence at these visits, patients' compliance was assessed, standard medication was adjusted as appropriate, and all interventions, outcome events, and adverse events were recorded. The patients were followed for the occurrence of major adverse cardiac events (MACE), defined as follows: 1) cardiogenic death; 2) myocardial infarction (hospital visit for myocardial infarction reported by patient or hospital admission for myocardial infarction reported by cardiologist); and 3) cerebrovascular accidents. Occurrence of major bleeding and chest pain, and functional capacity exercise (assessed with exercise tolerance test) were also evaluated. Additional variables that will be collected at baseline include demographic and clinical characteristics of patients as follows: sex (male, female), age (mean (SD)), hypertension (yes/no), and diabetes mellitus (yes/no).

To document any unfavorable occurrences, the patients were questioned via telephone monthly about any potential side effects.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 87 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients older than 18 undergoing primary isolated coronary bypass surgery, with or without cardiopulmonary bypass

Exclusion Criteria:

* Other cardiac surgeries except for coronary bypass surgery
* Left ventricular ejection fraction \< 30 %
* Liver disease
* Clopidogrel or aspirin intake within 7 days of operation
* Need for perioperative warfarin
* Active gastroduodenal ulcer or post-operative gastrointestinal bleeding
* Profuse post-operative pleural effusion (drainage \>200 ml/h for 2 h or more
* Postoperative low cardiac output syndrome or requirement for high levels of hemodynamic support (more than 2 inotropes for more than 24 h and/or intra-aortic balloon pump)
* Clinical instability, such as perioperative myocardial infarction or malignant tumor.
```

## Arms

- **aspirin and rivaroxaban** (EXPERIMENTAL) — post coronary bypass patients, received aspirin 80 mg and rivaroxaban 2.5 mg PO twice daily
- **aspirin** (ACTIVE_COMPARATOR) — post coronary bypass patients, received aspirin 80 mg

## Interventions

- **Rivaroxaban and aspirin 80** (DRUG) — rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
- **Aspirin 80** (DRUG) — aspirin 80 mg orally post coronary bypass surgery

## Primary Outcomes

- **MACE** _(time frame: 1 year)_ — Major adverse cardiac events (MACE), defined as follows: 1) cardiogenic death; 2) myocardial infarction (hospital visit for myocardial infarction reported by patient or hospital admission for myocardial infarction reported by cardiologist) ,and 3) cerebrovascular accidents
- **bleeding** _(time frame: 1 year)_ — all types of reported bleeding, major or minor

## Secondary Outcomes

- **functional capacity** _(time frame: 1 year)_

## Locations (1)

- Professor Kojuri Cardiology Clinic, Shiraz, Fars, Iran

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.professor kojuri cardiology clinic|shiraz|fars|iran` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06019741.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06019741*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*